Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose (glucose) is a monosaccharide that serves as a substrate for cellular metabolism, providing energy and restoring blood glucose levels. Sodium chloride (0.45%) provides electrolytes and helps maintain osmolality; the hypotonic solution replaces fluid and electrolytes.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Intravenous replenishment of fluids and calories in patients who cannot take orally,Maintenance of hydration and electrolyte balance,Treatment of hypovolemia,Prevention of dehydration
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
Intravenous infusion; dose depends on fluid and electrolyte needs. Typical adult rate: 100-200 m L/hour (2-4 m L/kg/hour) for maintenance. Maximum infusion rate: 25 m L/kg/hour. Not to exceed 50 m L/kg/24 hours.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
The terminal half-life of infused dextrose is not applicable as glucose is rapidly metabolized; however, exogenous glucose infusion is cleared with a half-life of approximately 15-30 minutes due to insulin-mediated uptake. Sodium and chloride have no defined elimination half-life as they are homeostatically regulated.
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Dextrose is metabolized via glycolysis and the Krebs cycle in cells; sodium and chloride are excreted renally and via sweat; no significant hepatic metabolism.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Dextrose is completely metabolized to carbon dioxide and water, with negligible renal excretion of intact glucose under normal conditions. Sodium and chloride are freely filtered by the glomerulus and undergo variable tubular reabsorption; excess is excreted renally. No biliary or fecal elimination.
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
Dextrose: not bound to plasma proteins. Sodium: negligible protein binding. Chloride: not significantly protein bound.
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
Dextrose distributes into total body water, approximately 0.55-0.6 L/kg in adults. Sodium and chloride distribute primarily into extracellular fluid, with volumes of distribution of approximately 0.2 L/kg for sodium and 0.25 L/kg for chloride. These reflect rapid equilibration in respective compartments.
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
Intravenous: 100% for dextrose, sodium, and chloride. Not applicable for other routes as this formulation is for IV use only.
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
GFR <10 m L/min: Avoid or use with caution due to risk of fluid overload and hypernatremia. GFR 10-50 m L/min: Monitor serum sodium and fluid status; adjust rate as needed. No specific dose reduction, but infusion rate may need to be decreased.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
No specific adjustment required for Child-Pugh class A or B. For Child-Pugh class C: Use with caution due to potential fluid retention; monitor serum sodium and adjust rate accordingly.
No dosage adjustment required for hepatic impairment.
Intravenous infusion; dose based on weight and clinical condition. Typical maintenance: 2-4 m L/kg/hour for children. For neonates, rate may be adjusted to 80-100 m L/kg/day. Do not exceed 25 m L/kg/hour.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Elderly patients: Start at lower end of dosing range (e.g., 100 m L/hour) and titrate based on fluid status, renal function, and cardiac reserve. Monitor for signs of fluid overload and electrolyte imbalance.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
Not for use in patients with intracranial or intraspinal hemorrhage, or in patients with known hypersensitivity to corn-derived products. Do not administer to patients with anuria. Use with caution in patients with congestive heart failure, renal failure, or hyperglycemia.
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
Risk of hyperglycemia and hyperosmolarity, especially in diabetic or stressed patients,Monitor serum glucose and electrolytes,Use with caution in renal impairment, heart failure, and increased intracranial pressure,Hypotonic solution; may cause hemolysis if administered rapidly,Do not use if solution is discolored or contains particulates
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Hypersensitivity to dextrose or corn products,Intracranial or intraspinal hemorrhage,Anuria,Severe hyperglycemia with marked glycosuria,Patients with known allergy to any component
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
No specific food interactions. However, patients should avoid excessive salt or sugar intake unless directed by a healthcare provider.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
Deferral: Normal maternal glucose homeostasis is essential for fetal development; administration of 5% dextrose is not expected to increase teratogenic risk when properly monitored. Hyperglycemia or fluid/electrolyte imbalances may pose fetal risks. No first trimester data suggest direct teratogenicity.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Both dextrose and sodium chloride are normal constituents of breast milk. Maternal administration at isotonic and isosmotic concentrations does not alter milk composition measurably. M/P ratio not applicable as endogenous substances. Generally considered compatible with breastfeeding.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
Increased plasma volume (30-50%) and glomerular filtration rate during pregnancy may alter pharmacokinetics; however, dextrose and sodium chloride are endogenous substances regulated by homeostasis. No specific dose adjustment required except to monitor and adjust infusion rate based on maternal glucose, hydration status, and electrolyte levels. Pregnancy may unmask glucose intolerance; titrate dextrose infusion to avoid hyperglycemia.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
Dextrose 5% and sodium chloride 0.45% is a hypotonic solution. Use cautiously in patients at risk for increased intracranial pressure (e.g., traumatic brain injury) as rapid administration may cause cerebral edema. Avoid in patients with hyperglycemia, as dextrose can worsen glycemic control. Monitor serum sodium closely in patients with impaired renal function or syndrome of inappropriate antidiuretic hormone (SIADH) to prevent hyponatremia.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
Tell your healthcare provider if you have diabetes, heart failure, kidney disease, or are on a low-salt diet.,Report symptoms like headache, nausea, confusion, or swelling during the infusion.,Do not consume additional salt or sugar without medical advice while receiving this solution.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose (glucose) is a monosaccharide that serves as a substrate for cellular metabolism, providing energy and restoring blood glucose levels. Sodium chloride (0.45%) provides electrolytes and helps maintain osmolality; the hypotonic solution replaces fluid and electrolytes.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Intravenous infusion; dose depends on fluid and electrolyte needs. Typical adult rate: 100-200 m L/hour (2-4 m L/kg/hour) for maintenance. Maximum infusion rate: 25 m L/kg/hour. Not to exceed 50 m L/kg/24 hours.. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Deferral: Normal maternal glucose homeostasis is essential for fetal development; administration of 5% dextrose is not expected to increase teratogenic risk when properly monitored. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.